✦ LIBER ✦

PCN21 FIRST-LINE BEVACIZUMAB-BASED THERAPY VERSUS PEMETREXED + CISPLATIN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA NONSQUAMOUS NON-SMALL CELL LUNG CANCER: INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

✍ Scribed by K Berenson; C Chouaid; A Vergnenegre; S Sherman; S Walzer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN20 MAINTENANCE ERLOTINIB VERSUS PEMET

✍ R Casciano; H Bischoff; M Nuijten; E Malangone; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

PCN20 THE BUDGETARY IMPACT OF PEMETREXED

✍ RC Wielage; CE Muehlenbein; AM Liepa; SM Babineaux; RW Klein; LS Schwartzberg 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Comparative effectiveness of bevacizumab

✍ Gee-Chen CHANG; Myung-Ju AHN; Elaine WRIGHT; Heung Tae KIM; Joo-Hang KIM; Jin Hy 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

An indirect comparison of bevacizumab pl

✍ John Wen-Cheng CHANG; Sumitra THONGPRASERT; Elaine WRIGHT; Kenneth TSANG; Heung 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

PCN43 COST COMPARISON OF ERLOTINIB VERSU

✍ S Ravera; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

PCN44 COST COMPARISON OF ERLOTINIB VERSU

✍ J Castro de Carpeño; AJ Castro-Gómez; S Walzer; J Ray 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB